Oyster Point announced that its nasal spray will become available next month for patients with a prescription, making it the first FDA-approved nasal spray in the US for chronic dry eye disease. The drug is aimed at filling the unmet medical need for people who suffer from the disease, characterized by stinging, sensitivity to light, blurred vision and eye fatigue and affects around 38 million patients in the US. Oyster Point’s spray will need to be administered twice a day, with the drug’s approval based on trials that included more than 1000 patients with mild to severe dry eye disease. Currently dry eye disease is treated using over the counter drugs including GenTeal and Refresh.
Read more here.
More on: FDA News Regulatory